Kim Ji Hee, Chang In Bok, Kim Yoo Hwan, Min Chan Yang, Yoo Dae Myoung, Choi Hyo Geun
Department of Neurosurgery, Hallym University College of Medicine, Anyang, South Korea.
Department of Neurology, Hallym University College of Medicine, Anyang, South Korea.
Front Aging Neurosci. 2022 Mar 3;14:821235. doi: 10.3389/fnagi.2022.821235. eCollection 2022.
Despite the numerous studies on coronavirus disease 2019 (COVID-19), data regarding the impact of pre-existing diagnoses of Alzheimer's disease (AD) and Parkinson's disease (PD) on the susceptibility to and outcome of COVID-19 are limited. We aimed to determine whether patients with AD/PD had a higher likelihood of contracting COVID-19 and experiencing worse outcomes.
Data from patients with confirmed diagnoses of COVID-19 ( = 8,070) from January to June 2020 and control participants ( = 121,050) who were randomly selected to match the patients on the basis of age and sex were extracted from the Korean National Health Insurance Database. Pre-existing diagnoses of AD and PD were identified based on medical claim codes. The associations of pre-existing AD or PD with contracting COVID-19, developing severe COVID-19 and dying due to COVID-19 were examined using a logistic regression model. The participants' age, sex, income, comorbidity score, and history of hypertension/diabetes were assessed as covariates.
COVID-19 cases were more likely to have a pre-existing AD diagnosis (adjusted odds ratio [aOR] = 2.11, 95% confidence interval [CI] = 1.79-2.50, -value < 0.001) than controls. COVID-19 cases were more likely to have a pre-existing PD diagnosis than controls, although this estimate did not quite reach statistical significance (aOR = 1.41, 95% CI = 1.00-2.00, -value = 0.054). Pre-existing AD was related to severe disease and mortality from COVID-19 (aOR = 2.21, 95% CI = 1.64-2.98; aOR = 2.21, 95% CI = 1.00-2.00). Pre-existing PD was not associated with mortality (aOR = 1.54, 95% CI = 0.75-3.16) but was associated with severe disease (aOR = 2.89, 95% CI = 1.56-5.35).
We found that COVID-19 infection was significantly associated with a pre-existing diagnosis of AD but not with a pre-existing diagnosis of PD. Patients with pre-existing AD had higher odds of developing severe COVID-19 and dying. Pre-existing PD was only associated with a higher odds of developing severe COVID-19.
尽管针对2019冠状病毒病(COVID-19)进行了大量研究,但关于阿尔茨海默病(AD)和帕金森病(PD)的既往诊断对COVID-19易感性和预后影响的数据有限。我们旨在确定AD/PD患者感染COVID-19并出现更差预后的可能性是否更高。
从韩国国民健康保险数据库中提取2020年1月至6月确诊为COVID-19的患者(n = 8070)以及根据年龄和性别随机选取以匹配患者的对照参与者(n = 121050)的数据。根据医疗理赔编码确定AD和PD的既往诊断。使用逻辑回归模型检验AD或PD既往诊断与感染COVID-19、发展为重症COVID-19以及死于COVID-19之间的关联。将参与者的年龄、性别、收入、合并症评分以及高血压/糖尿病病史作为协变量进行评估。
与对照组相比,COVID-19病例更有可能有AD既往诊断(调整比值比[aOR]=2.11,95%置信区间[CI]=1.79 - 2.50,P值<0.001)。COVID-19病例比对照组更有可能有PD既往诊断,尽管这一估计未完全达到统计学显著性(aOR = 1.41,95% CI = 1.00 - 2.00,P值 = 0.054)。AD既往诊断与COVID-19导致的重症疾病和死亡相关(aOR = 2.21,95% CI = 1.64 - 2.98;aOR = 2.21,95% CI = 1.00 - 2.00)。PD既往诊断与死亡率无关(aOR = 1.54,95% CI = 0.75 - 3.16),但与重症疾病相关(aOR = 2.89,95% CI = 1.56 - 5.35)。
我们发现COVID-19感染与AD既往诊断显著相关,但与PD既往诊断无关。有AD既往诊断患者发展为重症COVID-19和死亡的几率更高。PD既往诊断仅与发展为重症COVID-19的较高几率相关。